Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia
Blood Research · 2024-12 · 59 (1)
DOI: 10.1007/s44313-024-00046-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 24.12.2024. Verfasst von Daehun Kwag und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study investigated the occurrence of subsequent malignancies (SM) in adult patients with severe aplastic anemia (SAA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to address the lack of large-scale, long-term data on this complication.
Methods
A retrospective cohort analysis of 376 adult patients with SAA who underwent allo-HSCT between 2002 and 2021 at a single center was conducted. The incidence, risk factors, and survival impact of SM were also examined.
Results
During the follow-up period, 31 cases of SM (8.2%) were identified. Approximately one-third (32.3%) of SM cases were hematologic malignancies, including post-transplant lymphoproliferative disorder (16.1%), myelodysplastic neoplasm (6.5%), and acute myeloid leukemia (3.2%). Solid tumors accounted for 67.7% of cases, with thyroid cancer being the most prevalent (25.8%). The 15-year cumulative incidence of SM was 11.2%, and the hazard ratio for overall survival according to the development of SM was 16.25 ( p < 0.001). High-dose total body irradiation (TBI), anti-thymocyte globulin (ATG), and moderate-to-severe chronic graft-versus-host disease (GVHD) were identified as significant risk factors for subsequent malignancy. Post-transplant SAA patients exhibited a 3.54-fold higher observed cancer incidence than the expected incidence calculated from the age-, sex-, and calendar year-matched general population.
Conclusion
SM is a significant long-term complication in patients with posttransplant SAA and has a substantial survival impact. Patients receiving high-dose TBI or ATG, and those with moderate-to-severe chronic GVHD, require vigilant long-term monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea. jwlee@hyumc.com.
Zitieren
APA
Kwag, D., Park, S. S., Lee, S. E., Kim, H. J., & Lee, J. W. (2024). Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia. Blood Research, 59(1). https://doi.org/10.1007/s44313-024-00046-2
Vancouver
Kwag D, Park SS, Lee SE, Kim HJ, Lee JW. Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia. Blood Research. 2024;59(1). doi:10.1007/s44313-024-00046-2
BibTeX
@article{Kwag2024,
author = {Kwag, Daehun and Park, Sung-Soo and Lee, Sung-Eun and Kim, Hee-Je and Lee, Jong Wook},
title = {Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia},
journal = {Blood Research},
year = {2024},
volume = {59},
number = {1},
doi = {10.1007/s44313-024-00046-2}
}
EUVIMED